Lone Harild Ottesen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lone Harild Ottesen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
A Flyvbjerg
Institute of Experimental Clinical Research, Aarhus University Hospital, Denmark
1 shared publicationA. Flyvbjerg
1 shared publicationAllan Flyvbjerg
Medical Research Laboratory M, Aarhus University Hospital, Aarhus, Denmark
1 shared publication- Allan Flyvbjerg
Steno Diabetes Center Copenhagen , Capital Region of Denmark, 2730 Copenhagen , Denmark
1 shared publication - Else-Marie Bladbjerg
Department of Regional Health Research, University of Southern Denmark, Denmark
1 shared publication Erling Bjerregaard Pedersen
Department of Medicine, Holstebro Hospital, Holstebro and Aarhus University, Denmark
1 shared publication
Latest Publications
- 1 October 2001
- Published by Wiley in Liver International
- Vol. 21 (5) , 350-356
The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis
- 1 October 2001
- Published by Wiley in Liver International
- Vol. 21 (5) , 350-356
The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis
- Open Access
- 1 September 2001
- Published by Wolters Kluwer Health in Hepatology
- Vol. 34 (3) , 471-477
Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial
Octreotide seems to have a beneficial effect on variceal bleeding, and long-term administration for the prevention of rebleeding is currently being evaluated. Experimental studies have suggested a beneficial effect of chronic octreotide treatment on renal function, while clinical studies have shown variable effects. Twenty-five cirrhotic patients with portal hypertension were randomized in a double-blind design to placebo or a single subcutaneous dose of a long-acting formulation of octreotide (octreotide-LAR) (20 mg). Renal function tests were performed before dosing and repeated after 30 days. The patients were in sodium steady state at the time of study. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by a constant infusion clearance technique. Renal sodium handling was determined by lithium and sodium clearance measurements. Therapeutic serum levels of octreotide along with a reduction of insulin-like growth factor I (IGF-I) (P < .01) and an increase of IGF binding protein 1 (P < .05) were demonstrated. No effect of octreotide was observed on GFR, ERPF, or filtration fraction (GFR/ERPF). Changes in clearance and extraction fraction of sodium and lithium during octreotide treatment were not significantly different from those of placebo. In addition, no changes in free water clearance, urinary flow rate, or 24-hour Na excretion were demonstrated. A significant increase of mean arterial pressure (+5 mm Hg; P < .01) was observed after treatment with octreotide-LAR. It is concluded that in spite of increased arterial pressure, octreotide-LAR has no significant effect on renal hemodynamics and tubular function in clinically stable cirrhotic patients with portal hypertension. (Hepatology 2001;34:471-477.)
- 1 September 2001
- Published by Wolters Kluwer Health in Hepatology
- Vol. 34 (3) , 471-477
Open AccessEffects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial
Octreotide seems to have a beneficial effect on variceal bleeding, and long-term administration for the prevention of rebleeding is currently being evaluated. Experimental studies have suggested a beneficial effect of chronic octreotide treatment on renal function, while clinical studies have shown variable effects. Twenty-five cirrhotic patients with portal hypertension were randomized in a double-blind design to placebo or a single subcutaneous dose of a long-acting formulation of octreotide (octreotide-LAR) (20 mg). Renal function tests were performed before dosing and repeated after 30 days. The patients were in sodium steady state at the time of study. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by a constant infusion clearance technique. Renal sodium handling was determined by lithium and sodium clearance measurements. Therapeutic serum levels of octreotide along with a reduction of insulin-like growth factor I (IGF-I) (P < .01) and an increase of IGF binding protein 1 (P < .05) were demonstrated. No effect of octreotide was observed on GFR, ERPF, or filtration fraction (GFR/ERPF). Changes in clearance and extraction fraction of sodium and lithium during octreotide treatment were not significantly different from those of placebo. In addition, no changes in free water clearance, urinary flow rate, or 24-hour Na excretion were demonstrated. A significant increase of mean arterial pressure (+5 mm Hg; P < .01) was observed after treatment with octreotide-LAR. It is concluded that in spite of increased arterial pressure, octreotide-LAR has no significant effect on renal hemodynamics and tubular function in clinically stable cirrhotic patients with portal hypertension. (Hepatology 2001;34:471-477.)
- 1 July 1999
- Published by S. Karger AG in Digestive Surgery
- Vol. 16 (6) , 486-495
Protein C Activation during the Initial Phase of Experimental Acute Pancreatitis in the Rabbit
Background: Disturbances of coagulation and fibrinolysis are well-known systemic effects of acute necrotising pancreatitis (ANP). The purpose of this experimental study was to evaluate the initial events in the haemostatic activation during ANP in an animal model with relevance to the human situation. Methods: ANP was introduced in 7 rabbits by infusion of chenodeoxycholic acid in the pancreatic duct. Seven rabbits served as sham-operated controls. Serial measurements of coagulation variables (prothrombin time, activated partial thromboplastin time, FVII activity, fibrinogen, tissue factor activity), anticoagulant proteins (protein C, antithrombin) and fibrinolytic factors (tissue plasminogen activator, plasminogen activator inhibitor-1) were performed for 5 h. Results: ANP was confirmed by elevated serum amylase, development of ascites, and histological changes of the pancreas. A moderate activation of the coagulation system was found in both study groups. A significant decrease in protein C concentration from 1 h after the induction of ANP was found, whereas the response of antithrombin and the inhibition of the fibrinolytic system were similar in the 2 study groups. Microthrombosis of the lungs or kidneys was found in 2 rabbits with ANP. Conclusion: An immediate activation of protein C is a specific characteristic of the haemostatic activation in ANP in rabbits. This activation has not been described previously and the possible therapeutic implications ought to be studied.
- 1 July 1999
- Published by S. Karger AG in Digestive Surgery
- Vol. 16 (6) , 486-495
Protein C Activation during the Initial Phase of Experimental Acute Pancreatitis in the Rabbit
Background: Disturbances of coagulation and fibrinolysis are well-known systemic effects of acute necrotising pancreatitis (ANP). The purpose of this experimental study was to evaluate the initial events in the haemostatic activation during ANP in an animal model with relevance to the human situation. Methods: ANP was introduced in 7 rabbits by infusion of chenodeoxycholic acid in the pancreatic duct. Seven rabbits served as sham-operated controls. Serial measurements of coagulation variables (prothrombin time, activated partial thromboplastin time, FVII activity, fibrinogen, tissue factor activity), anticoagulant proteins (protein C, antithrombin) and fibrinolytic factors (tissue plasminogen activator, plasminogen activator inhibitor-1) were performed for 5 h. Results: ANP was confirmed by elevated serum amylase, development of ascites, and histological changes of the pancreas. A moderate activation of the coagulation system was found in both study groups. A significant decrease in protein C concentration from 1 h after the induction of ANP was found, whereas the response of antithrombin and the inhibition of the fibrinolytic system were similar in the 2 study groups. Microthrombosis of the lungs or kidneys was found in 2 rabbits with ANP. Conclusion: An immediate activation of protein C is a specific characteristic of the haemostatic activation in ANP in rabbits. This activation has not been described previously and the possible therapeutic implications ought to be studied.
- 31 December 1998
- Published by Elsevier in Journal of Hepatology
- Vol. 28, 134
Octreotide in cirrhotic patients
- 31 December 1998
- Published by Elsevier in Journal of Hepatology
- Vol. 28, 134
Octreotide in cirrhotic patients
- Open Access
- 1 July 1998
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 12 (7) , 657-665
The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients
Background: Intravenous octreotide is an established treatment of oesophageal variceal haemorrhage in the cirrhotic patient. Aim: To examine the organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients with portal hypertension. Methods: Thirteen patients with cirrhosis had hepatic venous catheterization performed. Hepatic venous pressure gradient (HVPG), indocyanine green (ICG) clearance and hepatic blood flow (HBF) were determined in the basal state and during 60 min of octreotide infusion by bolus injection (0.75 μg/kg) followed by continuous infusion of 0.75 μg/kg.h. Blood samples were simultaneously drawn from the femoral artery and the hepatic and renal veins. Results: The extraction fraction of octreotide in the liver was 0.05 (− 0.01–0.14) (median (interquartile range)) and in the kidneys 0.16 (− 0.06–0.35). The extraction fraction ratio (Eliver/Ekidney) was 0.69 (− 0.20–1.06). Hepatic clearance was 47 mL/min (3–88) (n = 11). No correlations were found between liver biochemistry or galactose elimination capacity (GEC; a metabolic measure of liver function) and renal extraction fraction or liver clearance. Octreotide had no effect on HVPG or wedged hepatic venous pressure although free hepatic venous pressure increased during octreotide infusion: 6 mmHg (5–9) vs. 7 mmHg (6–10) (P = 0.02). No effect on HBF was observed while ICG clearance decreased significantly. Conclusions: Octreotide is extracted in cirrhotic patients by both the liver and the kidney, the latter being the most important organ of elimination. Octreotide decreases liver metabolic activity determined by the ICG clearance technique, but no significant effects of octreotide on HVPG or HBF could be demonstrated.
- 1 July 1998
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 12 (7) , 657-665
Open AccessThe organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients
Background: Intravenous octreotide is an established treatment of oesophageal variceal haemorrhage in the cirrhotic patient. Aim: To examine the organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients with portal hypertension. Methods: Thirteen patients with cirrhosis had hepatic venous catheterization performed. Hepatic venous pressure gradient (HVPG), indocyanine green (ICG) clearance and hepatic blood flow (HBF) were determined in the basal state and during 60 min of octreotide infusion by bolus injection (0.75 μg/kg) followed by continuous infusion of 0.75 μg/kg.h. Blood samples were simultaneously drawn from the femoral artery and the hepatic and renal veins. Results: The extraction fraction of octreotide in the liver was 0.05 (− 0.01–0.14) (median (interquartile range)) and in the kidneys 0.16 (− 0.06–0.35). The extraction fraction ratio (Eliver/Ekidney) was 0.69 (− 0.20–1.06). Hepatic clearance was 47 mL/min (3–88) (n = 11). No correlations were found between liver biochemistry or galactose elimination capacity (GEC; a metabolic measure of liver function) and renal extraction fraction or liver clearance. Octreotide had no effect on HVPG or wedged hepatic venous pressure although free hepatic venous pressure increased during octreotide infusion: 6 mmHg (5–9) vs. 7 mmHg (6–10) (P = 0.02). No effect on HBF was observed while ICG clearance decreased significantly. Conclusions: Octreotide is extracted in cirrhotic patients by both the liver and the kidney, the latter being the most important organ of elimination. Octreotide decreases liver metabolic activity determined by the ICG clearance technique, but no significant effects of octreotide on HVPG or HBF could be demonstrated.